Abstract
Multiple myeloma is a severe malignance caused by damaged B cells from bone marrow plasma cells. Multiple treatments have been introduced to release and treat such a disease, but in general, high rate and severity of adverse events and relatively unideal efficacies of those existing treatments necessitate a new therapy achieving a better curative effect. Thus, CARVYKTI, a CAR-T therapy, has been developed for treat patients with multiple myeloma and who have already received several other treatments. By having genetically modified T cells, damaged cancer-causing B cells are targeted and vanished specifically. Recently, the FDA has officially approved CARVYKTI as a treatment for refractory multiple myeloma, and the basic pharmacology and the phase1b-2 clinical trial are summarized in this paper.
Publisher
Darcy & Roy Press Co. Ltd.
Reference11 articles.
1. Berdeja, J.G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study, The Lancet, Volume 398, Issue 10297, Pages 314-324. (2021).
2. US Food and Drug Administration (2022). Summary Basis for Regulatory Action, BLA 125746/0.
3. Kumar, S., Rajkumar, V., Kyle, R. et al. Multiple myeloma. Nat Rev Dis Primers 3, 17046 (2017).
4. Wang, H., Kaur, G., Sankin, A.I. et al. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol 12, 59 (2019). https://doi.org/10.1186/s13045-019-0746-1
5. The American Cancer Society medical and editorial content team (2021). Drug Therapy for Multiple Myeloma. https://www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy.html